Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

504 public trials 140 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

NCT00702052

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic - Arizona Mayo Clinic - Scottsdale Multiple Locations, Arizona, United States
  • Highlands Oncology Group DeptofHighlandsOncologyGrp(2) Fayetteville, Arkansas, United States
  • Bay Area Cancer Research Dept.ofBayAreaCancerResearch Concord, California, United States
  • City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) Duarte, California, United States
View all 31 locations
View Trial Details
Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

NCT02910063

Conditions
B-cell Non Hodgkin Lymphoma, Disease Attributes, Hematologic Diseases, +14 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Baltimore, Maryland, United States
  • Research Site Oklahoma City, Oklahoma, United States
  • Research Site Greenville, South Carolina, United States
View all 31 locations
View Trial Details
Completed

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

NCT02900716

Conditions
B-cell Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +18 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

A Study for Patients With Non-Hodgkin's Lymphomas

NCT00542919

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Anaheim, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Garran, Australian Capital Territory, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gosford, New South Wales, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Auchenflower, Queensland, Australia
View all 14 locations
View Trial Details
Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

NCT02945215

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing cancer hospital Beijing, Beijing Municipality, China
  • Peking University third hospital Beijing, Beijing Municipality, China
  • The 307th Hospital of Military Medical Sciences Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Haerbin, Heilongjiang, China
View Trial Details

Related conditions